Matinas BioPharma Holdings, a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, has appointed Dominick DiPaolo as Senior Vice President of Quality and Regulatory Compliance.
DiPaolo joins the Matinas team having most recently served as the Senior Vice President of Quality, Compliance and Regulatory Affairs at Cyalume Technologies, the company said.
Roelof Rongen, Chief Executive Officer of Matinas commented: “We are excited to welcome Dominick to the Matinas executive team. His broad pharmaceutical experience and expertise in the areas of quality and regulatory compliance will prove to be invaluable as we continue to drive our clinical development and regulatory strategies forward for our lead programs, MAT2203 and MAT2501, and work to build out our internal formulation and manufacturing capabilities.”